gdc
FDA Approvals, News & UpdatesLiver CancerNewsworthy

Stivarga and Opdivo Newest Treatments for Liver Cancer

In 2017, the FDA approved two new treatments for patients with hepatocellular carcinoma (HCC), Stivarga and Opdivo. Read about these new treatments for liver cancer.
December 2017 Vol 3 No 6

On April 27, 2017, the FDA approved Stivarga (regorafenib, from Bayer HealthCare) for the treatment of patients with the most common type of liver cancer, called hepatocellular carcinoma (HCC), after they received sorafenib.

Stivarga, a kinase inhibitor that blocks the activity of several enzymes that promote cancer growth, is the first drug in almost a decade to be approved by the FDA for liver cancer. Stivarga was previously approved for the treatment of patients with colorectal cancer or gastrointestinal stromal tumors that stopped responding to other treatments.

On September 26, 2017, the FDA approved Opdivo (nivolumab, from Bristol-Myers Squibb), for patients with HCC, after being treated with sorafenib. Opdivo is the first immunotherapy approved by the FDA for patients with HCC and the second new treatment approved in the past decade for liver cancer.

The FDA approval of Opdivo for liver cancer was based on a study showing that 22 patients responded to treatment with Opdivo; of these patients, the cancer was in complete remission in 3 patients after treatment with Opdivo, and 19 patients saw their tumors shrink significantly. Opdivo was previously approved for many other types of cancer.

Share this:

Recommended For You
FDA Approvals, News & UpdatesBreast Cancer
Verzenio First CDK4/6 Approved with Endocrine Therapy for Adjuvant Treatment of Early Breast Cancer
In October 2021, the FDA approved the combination of Verzenio (abemaciclib), a CDK 4/6 inhibitor, plus endocrine therapy for adjuvant treatment (after surgery) of adults with HR-positive, HER2-negative, node-positive, early breast cancer that is at high risk of recurrence.
FDA Approvals, News & UpdatesMultiple Myeloma
Darzalex Faspro, Kyprolis, and Dexamethasone a New Combination Approved for Multiple Myeloma
In November 2021, the FDA approved the combination of subcutaneous Darzalex Faspro (daratumumab and hyaluronidase) plus Kyprolis (carfilzomib) and dexamethasone for adults with relapsed or refractory multiple myeloma who have received previous therapy.
FDA Approvals, News & UpdatesKidney Cancer
Keytruda FDA Approved for Adjuvant Treatment of Kidney Cancer
In November 2021, the FDA approved a new indication for the immunotherapy Keytruda (pembrolizumab) for adjuvant treatment (after surgery) of patients with renal-cell carcinoma that is at intermediate-high or high risk for recurrence.
FDA Approvals, News & UpdatesCervical Cancer
Keytruda plus Chemotherapy FDA Approved for First-Line Treatment of Cervical Cancer
In October 2021, the FDA approved the immunotherapy Keytruda (pembrolizumab), in combination with chemotherapy and with or without Avastin (bevacizumab), for patients with persistent, recurrent, or metastatic cervical cancer and PD-L1 expression.
Last modified: January 23, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest